Ruchit Patel
Partner
Ruchit Patel is an antitrust partner in the firm’s London office and a member of the firm’s governing policy committee. He advises some of the largest companies in the world on matters before the European Commission, UK Competition and Markets Authority, UK sectoral regulators, UK High Court. He also has litigation experience before the UK Competition Appeal Tribunal.
Ruchit was included in Global Competition Review’s 2020 list of the top young antitrust lawyers in the world: the 40 under 40. Who’s Who Legal characterizes him as a “Future Leader” and comments that “Ruchit Patel is revered as an “skilled, flexible and sharp-minded competition law expert” who is “able to coordinate complex projects.” Ruchit is also recognized in Chambers UK in the area of competition law, and GCR notes he is a “Future Leader.” Clients have commented in Who’s Who Legal that Ruchit is “a very experienced competition lawyer” who “focuses on strategy and results” and “is uniquely dedicated to ensuring his clients’ success” and is “able to coordinate complex projects.” Legal 500 also noted that Ruchit brings “an in-depth knowledge of Indian competition law.”
Ruchit is a visiting Lecturer at the Centre for Commercial Law Studies at Queen Mary University of London. He is a member of several committees, including the Competition Section of the English Law Society, the Law360 Editorial Board, and the Editorial Board of the IBA.
Experience
Representative Strategic Company Experience
- Pfizer Inc. on several transactions, including Biohaven (~$12 billion), Global Blood Therapeutics (~$5.4 billion), Trillium Therapeutics Inc. ($2.26 billion), Medivation ($14 billion) and others
- Medtronic on several transactions, including Covidien ($43 billion), Mazor Robotics ($1.64 billion), Affera (~$1 billion), Intersect ($1.1 billion) and others
- Google on its acquisition of an interest in Reliance Jio Platforms valued at $4.5 billion
- Acceleron Pharma on its approximately $11.5 billion sale to Merck
- Sunovion Pharmaceuticals, a subsidiary of Japan’s Sumitomo Dainippon Pharma, in a billion-dollar worldwide co-development and co-commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for four novel neurology drugs
- Takeda Pharmaceutical Company Limited in an exclusive collaboration and license agreement with JCR Pharmaceuticals Co., Ltd. to commercialize JR-141 for the treatment of Hunter syndrome
- Wright Medical Group N.V. on its agreement to be acquired by Stryker Corp. in a transaction with a total enterprise value of approximately $5.4 billion
- Blue Coat on the European aspects of its sale to Symantec valued at over US$4 billion
- Biomet, the divestiture buyer, on J&J’s US$21.3 billion acquisition of Synthes
- Merck on its animal health joint venture with Sanofi-Aventis (ultimately abandoned). Awarded GCR “Deal of the Year” in 2011 in recognition of its size and complexity
- Abbott on its US$4.5 billion acquisition of Solvay’s pharmaceuticals and diagnostics business, which was conditionally cleared at Phase
Representative Private Equity Experience
- TPG on its $4 billion sale of McAfee Enterprise to STG
- TPG on its $14 billion sale of McAfee Consumer to Advent International and Permira
- TPG on its $4 billion sale of Wind River to Aptiv
- Bain Capital on its US$18 billion acquisition of Toshiba Memory Corporation from Toshiba Corporation, by way of a Bain Capital-led consortium including Apple, Seagate Technology, Kingston Technology, Hoya, Dell Technologies and SK Hynix
- Baring Private Equity Asia on its ~$7 billion merger with EQT
- Bain Capital on its $8.5 billion acquisition of Hitachi Metals
- Advent International on its $2.7 billion acquisition of Nielsen IQ
- Warburg Pincus and General Atlantic on their $2 billion acquisition of Santander Asset Management
Investigations
- Google with several multi-jurisdictional competition law investigations
- The Coca-Cola Company in several transactions and in defence of its commercialization practices
- SK Hynix on settlement negotiations with the European Commission in DRAM
- IBM with a complaint to the European Commission in relation to “midrange” servers
- Metlac in defence of the Competition Commission’s decision to prohibit AkzoNobel’s acquisition of Metlac
- Boots plc in relation to Celesio’s appeal of the OFT’s decision in Boots/ Alliance Unichem in the Competition Appeal Tribunal
- An intervener in relation to Ofgem’s decision to fine British Gas for exclusionary policy in relation to gas and electricity matter
Publications
- Quoted, “Driving Greater Diversity Within the U.K.’s Competition Bar,” Global Competition Review (May 12, 2023)
- Co-author, “Merger Control & FDI Outlook for 2023,” Bloomberg Law (February 2023)
- Co-author, “United Kingdom,” GLI – Merger Control 2020 (May 2020)
- Quoted, “Merger changes aren’t necessary, Indian lawyers say,” Global Competition Review (August 17, 2018)
- Quoted, “Regulation is ‘greatest risk’ for PE managers,” Private Funds Management (September 29, 2017)
- Author, “The Development Of The European Commission’s Decisional Practice On Failing Division Defences,” World Competition, September 2015, (nominated for World Competition’s Legal Writing Award (Under 35 category))
- Author, “The Treatment of Late Filings in Indian Merger Control,” World Competition and Indian Lawyer, 2014
- Co-author, “Dominance,” EC Competition Law Series, Volume V: Abuse of Dominance Under Article 102 TFEU, Claeys & Casteels, September 2013
- Co-author, “Now the Commission Wants Damages Too… The Commission as Private Damages Claimant and Its Implications,” CPI Antitrust Chronicle, July 15, 2013 (nominated for Concurrences Legal Writing Award for Private Actions)
- Author, “Barmi v. the Board of Control for Cricket in India: One to Send Upstairs?” Kluwer Competition Law Blog, February 2013
- Author, “2013: The Wind of Change,” Competition Policy International, January 2013
- Author, “BIS Reforms to the UK Merger Regime: An Opportunity Missed,” Competition Law Journal, Volume 11/Issue 2, 2012
- Author, “The Removal of Dishonesty from the Cartel Offence and the Publication Defence: A Panacea?” CPI Antitrust Journal, Spring 2012
- Author, “The Development of UK Jurisprudence on Hub and Spoke Cartels,” Global Competition Review, October 2010
- Author, “The English Court of Appeal’s Judgment in Cooper Tire,” Competition Policy International, August 2010
- Author, “Deliberate Concealment in Cartel Claims,” Competition Policy International, May 2010
- Guest Editor, Competition Policy International Issue, May 2010
- Author, “Oral Hearings and the Best Practices Guidelines,” Competition Policy International, March 2010
Presentations
- Speaker, “Article 22 Referrals – What Happened to Legal Certainty?,” The Law Society’s International Summer Antitrust Conference (June 23, 2021)
- Speaker, “Competition and Digital Platforms,” King’s College London Public Policy Workshop (December 13, 2019)
- Moderator, “Navigating the Regulatory Landscape in Private Equity,” Kayo Women's Private Equity 5th Annual Conference (October 3, 2017)
- Organizer and Participant, Private Equity General Counsel Roundtable (June 27, 2017)
- Speaker, “Proof Agreements, Incentives and Liabilities in Hub-and-Spoke Antitrust Conspiracies,” The Knowledge Group Webinar (May 16, 2017)
- Speaker, “Online Platforms and Competition Law: Challenges for Competition Authorities and Policy Matters,” The Center for Innovation, Intellectual Property and Competition (May 4, 2017)
- Co-host, “Competition in Digital Markets”, U.S.-India Business Counsel Roundtable Discussion (March 29, 2017)
- Speaker, 3rd International Competition Law Conference (November 12, 2016)
Disclaimer
Ropes & Gray International LLP is a limited liability partnership registered in Delaware, United States of America and is a recognised body regulated by the Solicitors Regulation Authority (with registered number 521000).Ropes & Gray (Ireland) LLP is authorized as a limited liability partnership by the Legal Services Regulatory Authority under the Legal Services Regulation Act 2015 (Registration number: 1262568).
Education
- LPC, Commendation, Nottingham Law School, 2004
- LLB, First Class Honours, University of Wales, Aberystwyth, 2002
- JD, First Class Honours, Universität Würzburg Faculty of Law, 2001
Admissions / Qualifications
Qualifications
- England and Wales, Solicitor, 2006
- Ireland, Solicitor, 2016
Awards
- LMG Life Sciences Americas Awards “Impact Deal of the Year” for advising Pfizer in $11.6 billion acquisition of Biohaven Pharmaceuticals (2022)
- Asia Legal Awards – Private Equity Deal of the Year (2022): Kuehne+Nagel's US$1.5 billion acquisition of Apex International; Advised MBK Partners in the sale
- BTI Client Service All-Star (2022)
- Deal of Distinction (2021) in the life sciences category by the Licensing Executive Society for a global licensing collaboration to develop small molecule inhibitors for treatment of Parkinson’s disease and movement disorders
- Chambers UK (2020-2022)
- Global Competition Review 2020—"40 Under 40"
- Global Competition Review 2019—Recognized as a “Future Leader”
- The Legal 500 US (2018-2019)
- The Legal 500 UK, EU and Competition (2020)
- Who’s Who Legal: Competition Future Leaders (2019)
